Insight

Erman Akkus: Our new study Prostate Cancer and PARPi

Photo from Erman Akkus/X

Apr 30, 2024, 19:43

Erman Akkus: Our new study Prostate Cancer and PARPi

Erman Akkus, Medicine Oncology and Internal Medicine Specialist at Ankara University, shared on X:

“Our new study has been published!
Coskun Yazgan, Emre Yekedüz, Yüksel Ürün.

Prostate Cancer and PARPi: Thromboembolic Risk
Increased risk of thrombosis with PARPi compared to controls: 4.3% vs. 2.2%, OR:1.98, 95% CI: 1.06-3.70, P=0.030
Should be considered when deciding prophylaxis in patients with prostate cancer treated with PARPi.

Thanks a lot to Yüksel Ürün and Emre Yekedüz for their support and mentoring. What a great chance to be in the same department!”

Erman Akkus

Source: Erman Akkus/X
OncoDaily

cancer Cancer research cancer treatment cancer treatment side effects Coskun Yazgan Emre Yekedüz Erman Akkus healthcare news Medical News Medical Publication Medical Research Medical Research Paper Medical Study Medical Study Findings Medical Study Results OncoDaily Oncology oncology research PARP inhibitors PARPi prostate cancer Prostate cancer treatment Research research findings Thromboembolic Risk Thrombosis Prevention Thrombosis Risk Yüksel Ürün

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage